ClinicalTrials.gg
WithdrawnNCT04748939Updated Oct 1, 2026

Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT

A Phase 4 interventional study of recombinant subunit herpes zoster vaccine in Herpes Zoster, sponsored by Tuen Mun Hospital. Withdrawn at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Tuen Mun Hospital · Phase 4, Interventional, and Prevention

How we know

Why this study was withdrawn
lack of funding
Updated Oct 1, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
46th of 46
0 · median 239
Started
2026
with 2 others
Phase 4
8 of 46
4 open now
Registered
33rd of 46
by date

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 46th largest by enrollment, is one of 3 that started in 2026, is one of 8 in phase 4, and was the 33rd registered.

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies

Read the detailed description

A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies.

Duration of study: 60 weeks

03

Conditions studied

  • Herpes Zoster

Keywords

  • vaccine
  • rheumatic diseases
  • immunosuppressive
  • immunogenicity
  • biologics
  • targeted DMARDs
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a diagnosis of rheumatic or immune-mediated diseases eg. SLE, RA, PSA, SpA, inflammatory myopathies, ANCA-related and large vessel vasculitides
  2. Age ≥18 years
  3. Stable or reducing doses of any the following regimens within 4 weeks of study entry:

    1. Prednisolone ≥20mg/kg/day ± mycophenolate mofetil, azathioprine or the calcineurin inhibitors
    2. Cyclophosphamide (intravenous pulses or daily oral)
    3. B-cell depleting biological agents and their biosimilars eg. belimumab, anti-CD20 agents (next scheduled dose should be arranged to at least 12 weeks after study entry for rituximab or obinutuzumab)
    4. Anti-TNFα biological agents and their biosimilars eg. infliximab, etanercept, adalimumab, golimumab, certolizumab
    5. Anti-interleukin-6 biological agents eg. tocilizumab, sarilumab
    6. Other biological agents eg. abatacept, ustekinumab, secukinumab, ixekizumab
    7. The JAK inhibitors eg. tofacitinib, baricitinib, upadacitinib
  4. Female patients with are allowed to participate in this study provided that they are willing to practice for until at least 12 months after vaccination
  5. Willing to comply with all study procedures

Exclusion criteria

Exclusion criteria for patients:

  1. Active infection, including upper respiratory tract infection
  2. Active HZ infection
  3. Active untreated tuberculosis
  4. infection
  5. History of HZ or varicella vaccination in the past
  6. History of allergy to any vaccines
  7. Patients who are pregnant or plan to become pregnancy within one year of study entry
  8. Lactating women
  9. Patients who cannot give a written consent (mentally incapable or illiterate)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    vaccine

    Shingrix vaccine

    Biological: recombinant subunit herpes zoster vaccine

  • Placebo comparator
    placebo

    normal saline injection (0.5mL)

    Biological: recombinant subunit herpes zoster vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. humoral immune response to Shingrix

    proportion of patients with 4x fold increase in anti-gE antibody titer

    Time frame: week 12 (compared with baseline)

Secondary outcomes

  1. Humoral immune response

    proportion of patients with 4x fold increase in anti-gE antibody titer

    Time frame: week 52

  2. adverse events

    solicited

    Time frame: 7 days after injection

  3. adverse events

    unsolicited

    Time frame: 4 weeks after injection

  4. flares of underlying diseases

    disease flares

    Time frame: week 26 and 60

  5. herpes zoster infection

    herpes zoster infection

    Time frame: week 60

  6. cell mediated response to vaccine

    in 40 patients (20 from each arm); number of IFNγ-secreting CD4+ T cell colonies on ELISPOT assay

    Time frame: week 12 from baseline

07

Study locations

1 site
  • Department of Medicine, Tuen Mun Hospital
    Hong Kong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2026 to primary completion in Sep 2026, 0 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Jan 2025 → Sep 2026, primary completion Dec 2025 → Sep 2026 and completion Jul 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2021
First posted
Feb 10, 2021
StartActual
Sep 29, 2026was Jan 2025
Primary completionActual
Sep 29, 2026was Dec 2025
CompletionActual
Sep 29, 2026was Jul 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn lack of funding
changed Oct 1, 2026
Start date
Jan 2025→Sep 29, 2026 (actual)
Oct 1, 2026
Primary completion
Dec 2025→Sep 29, 2026 (actual)
Oct 1, 2026
Study completion
Jul 2026→Sep 29, 2026 (actual)
Oct 1, 2026
Enrollment
140 (estimated)→0 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Withdrawn
    Why stopped lack of funding
    Start date Jan 2025→Sep 29, 2026 (now actual)
    Primary completion Dec 2025→Sep 29, 2026 (now actual)
    Study completion Jul 2026→Sep 29, 2026 (now actual)
    Enrollment 140 (estimated)→0 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04748939
Lead sponsor
Tuen Mun Hospital
Responsible party
Chi Chiu Mok (Dr, Tuen Mun Hospital) — Principal investigator
First posted
Feb 10, 2021
Start date
Sep 29, 2026
Primary completion
Sep 29, 2026
Completion
Sep 29, 2026
Last update
Oct 1, 2026

Study contacts

Chi Chiu Mok
principal investigator · Tuen Mun Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion